Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?